Vanderbilt University Medical Center (VUMC) is the first in the state to enroll patients in a clinical trial testing the effectiveness of the newest implantable device used to reduce stroke risk in patients with non-valvular atrial fibrillation (AF), the most common form of arrhythmia.
Peggy Tubb doesn’t recall her exact reaction when she was told she could stop taking blood thinners to treat atrial fibrillation (AF), but the news changed her life.
The irregular heart rhythm atrial fibrillation increases the risk of death in patients in the intensive care unit.
Vanderbilt Heart and Vascular Institute now offers patients with atrial fibrillation (AF) an alternative treatment to reduce their risk of stroke, potentially avoiding the long-term use of blood thinners such as warfarin.
Growing evidence suggests that fish oil, thought to directly prevent inflammation, oxidative stress and heart disease, may have limited clinical utility.
New findings suggest that misfolded proteins accumulate in the heart atria, particularly in patients with hypertension, and may contribute to atrial heart disease.
Accessibility Tools